irinotecan,leucovorin,oxaliplatin,nab-paclitaxel,gemcitabine
Ipsen
[]
 on the ground at #gi23: results from napoli-3, co-authored by vhio s , show 1st line nalirifox improved overall survival vs. standard therapy in treatment-na ve patients with mpdac. 
Leading translational research to accelerate & advance personalized and targeted therapies against cancer. 
@iCERCA centre